With Medicxi’s backing, Kurome seeks best-in-class IRAK4 program for blood cancers
Emerging Company Profile: Kurome seeks edge in efficacy, durability for AML
With early clinical data emerging that suggest a combination of IRAK4 and FLT3 inhibition may be effective in treating acute myelogenous leukemia, Medicxi has thrown its weight behind Kurome, a spinout from Cincinnati Children’s Hospital Medical Center that believes it has a best-in-class program.
Based on the work of founder Daniel Starczynowski, a principal investigator in the hematologic malignancies program at the medical center, Kurome Therapeutics Inc. is developing a program that inhibits both IRAK1 and IRAK4 while also acting as a pan-FLT3 inhibitor...
BCIQ Company Profiles